Diabetes Mellitus, Hemodialysis Access Failure, Renal Failure
Conditions
Keywords
Diabetes Mellitus, Renal Failure, Hemodialysis Access Failure, Sclerostin
Brief summary
Background: Parathyroid hormone (PTH) and 1,25-dihydroxy vitamin D (1,25-OHD) as well as mineral bone metabolism modulators like sclerostin are thought to play an important role in in diabetic patients with chronic renal failure. The present study aimed to analyse the levels of serum sclerostin before and after hemodialysis which is a primary element of treatment in such combined disease states. Methods: Serum sclerostin concentrations were measured using a commercially available enzyme-linked immunosorbent assay kit with 56 individuals who 14 chronic hemodialysis patients with diabetes, 14 chronic hemodialysis patients with non-diabetes and 28 healthy volunteers as a control group.
Detailed description
Sclerostin results in a phenotype characterized by high bone mass (sclerosteosis) in humans, it is produced by osteocytes and chondrocytes, it suppresses osteoblast activity by inhibiting canonicular Wnt / β-catenin signal, it is described as an anti-anabolic protein of 22-kDa size.In diabetes mellitus patients osteoporosis and obesity always create problems, increased levels of sclerostin inhibit canonicular Wnt / β-catenin signal and is potentially held responsible from bone fragility. Bone problems are important both for chronic kidney disease patients and diabetes mellitus patients and in instances where these two diseases coexist, the importance of sclerostin as a new marker of bone turnover increases. The objective of this study is to evaluate how serum sclerostin levels are affected in diabetes mellitus patients undergoing hemodialysis treatment. To this end, the investigators analyzed the levels of serum sclerostin before and after hemodialysis as it is a main element of treatment in such combined disease states.
Interventions
DIAGNOSTIC_TESTserum sclerostin
blood samples obtained
Sponsors
Abant Izzet Baysal University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
44 Years to 74 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients who satisfied inclusion criteria signed informed consent forms before they enrolled in the study. * Chronic hemodialysis patients receiving treatment at our hospital. * The patients had Type 2 diabetes mellitus and the patients were not diabetic. * Healthy volunteers as a control group
Exclusion criteria
* Clinical diagnosis of chronic respiratory failure, acute kidney failure, nephrotic syndrome, end-stage liver disease, malignancy, acute infections * Any health problems necessitating urgent interventions, drinking alcohol and/or smoking as well as pregnant patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change from levels of serum sclerostin of Diabetic group in dialysis at 1 months | blood samples were obtained within 30 minutes of before and after dialysis | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). |
| change from levels of serum sclerostin of Non-diabetic group in dialysis at 1 months | blood samples were obtained within 30 minutes of before and after dialysis | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). |
| change from levels of serum sclerostin of control group | through study completion, an average of 1 day. | Sclerostin is an anti-anabolic protein of 22-kDa size, at a level of ng/mL. Serum concentrations are measured with an ELISA kit (Cloud-CloneCorp., Katy, TX 77494, USA). |
Countries
Turkey (Türkiye)
Outcome results
None listed